Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS

Open access
Baber, Usman, Dangas, George, Angiolillo, Dominick Joseph, Cohen, David Joel, Sharma, Samin Kumar, Nicolas, Johny, Briguori, Carlo, Cha, Jin Yu, Collier, Timothy, Dudek, Dariusz, Džavik, Vladimir, Escaned, Javier, Gil, Robert, Gurbel, Paul, Hamm, Christian W, Henry, Timothy, Huber, Kurt, Kastrati, Adnan, Kaul, Upendra, Kornowski, Ran, Krucoff, Mitchell, Kunadian, Vijay, Marx, Steven Owen, Mehta, Shamir, Moliterno, David, Ohman, Erik Magnus, Oldroyd, Keith, Sardella, Gennaro, Sartori, Samantha, Shlofmitz, Richard, Steg, Philippe Gabriel, Weisz, Giora, Witzenbichler, Bernhard, Han, Ya-Ling, Pocock, Stuart, Gibson, Charles Michael, Mehran, Roxana · 2020 · European Heart Journal

Abstract

Aims: The aim of this study was to determine the effect of ticagrelor monotherapy on clinically relevant bleeding and major ischaemic events in relation to clinical presentation with and without non-ST elevation acute coronary syndromes (NSTE-ACS) among patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Methods and results: We conducted a pre-specified subgroup analysis of The Ticagrelor With Aspirin or Alone in High Risk Patients After Coronary Intervention (TWILIGHT) trial, which enrolled 9006 patients with high-risk features undergoing PCI with DES. After 3 months of dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin, 7119 adherent and event-free patients were randomized in a double-blind manner to ticagrelor plus placebo versus ticagrelor plus aspirin for 12 months. The primary outcome was Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding while the composite of all-cause death, myocardial infarction (MI), or stroke was the key secondary outcome. Among patients with NSTE-ACS (n = 4614), ticagrelor monotherapy reduced BARC 2, 3, or 5 bleeding by 53% [3.6% vs. 7.6%; hazard ratio (HR) 0.47; 95% confidence interval (CI) 0.36–0.61; P < 0.001) and in stable patients (n = 2503) by 24% (4.8% vs. 6.2%; HR 0.76; 95% CI 0.54–1.06; P = 0.11; nominal P int = 0.03). Rates of all-cause death, MI, or stroke among those with (4.3% vs. 4.4%; HR 0.97; 95% CI 0.74–1.28; P = 0.84) and without (3.1% vs. 3.2%; HR 0.96; 95% CI 0.61–1.49; P = 0.85) NSTE-ACS were similar between treatment arms irrespective of clinical presentation (P int = 0.96). Conclusion: Among patients with or without NSTE-ACS who have completed an initial 3-month course of DAPT following PCI with DES, ticagrelor monotherapy reduced clinically meaningful bleeding events without increasing ischaemic risk as compared with ticagrelor plus aspirin. The benefits of ticagrelor monotherapy with respect to bleeding events were more pronounced in patients with NSTE-ACS. Trial registration: Clinicaltrials.gov identifier: NCT02270242.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehaa670

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 185

Metadata

Authors
Baber, U., Dangas, G., Angiolillo, D. J., Cohen, D. J., Sharma, S. K., Nicolas, J., Briguori, C., Cha, J. Y., Collier, T., Dudek, D., Džavik, V., Escaned, J., Gil, R., Gurbel, P., Hamm, C. W., Henry, T., Huber, K., Kastrati, A., Kaul, U., Kornowski, R., Krucoff, M., Kunadian, V., Marx, S. O., Mehta, S., Moliterno, D., Ohman, E. M., Oldroyd, K., Sardella, G., Sartori, S., Shlofmitz, R., Steg, P. G., Weisz, G., Witzenbichler, B., Han, Y.-L., Pocock, S., Gibson, C. M., & Mehran, R.
Venue
European Heart Journal
Published
2020-10-01
Volume
41
Issue
37
Pages
3533-3545
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3094217864
Cited by
185
References
9
FWCI
13.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. https://app.cochat.ai/papers/10.1093/eurheartj/ehaa670
The paper
Baber, U., Dangas, G., Angiolillo, D. J., Cohen, D. J., Sharma, S. K., Nicolas, J., Briguori, C., Cha, J. Y., Collier, T., Dudek, D., Džavik, V., Escaned, J., Gil, R., Gurbel, P., Hamm, C. W., Henry, T., Huber, K., Kastrati, A., Kaul, U., . . . Mehran, R. (2020). Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa670

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.